Source: Real Money Valeant Pharmaceuticals' (VRX) new CEO Joseph Papa may have spoken too soon in his pledge to begin to curb drug prices that had been hiked to controversial levels -- especially as the drugmaker's roughly $31 billion debt package did not come without strings attached. Lender-friendly covenants, such…...